Listing Details:

• Business Category:      Medical Related Biz
• Price:                              $70,000,000
• EBITDA:                         $13.56MM (Projected 5-Year                                                                        Average)
• Reason For Sale:           Position for Planned Growth Opportunities
• Years Owned:                10 Years

Business Description

A highly scalable, high-margin platform operating at the intersection of FDA-cleared clinical technology, supply chain resilience, and advanced enterprise intelligence.  

The Opportunity at a Glance

U.S. hospitals face mounting pressure to improve margins as reimbursement rates tighten and implant costs continue to rise. Many providers lack visibility into both the true cost of surgical implants and the reimbursement leakage that can occur across the care delivery cycle.

The Company has built a platform specifically designed to address this challenge. Through direct sourcing from a 30+ year European manufacturer with FDA-cleared product lines, the Company delivers premium-equivalent orthopedic, trauma, spine, and surgical products at substantially lower costs than many traditional branded alternatives.

Complementing the FDA cleared product lines is the company’s  AI-driven healthcare analytics platform designed to address these challenges. By combining advanced financial intelligence with a proprietary database of medical device cost information, the platform helps healthcare providers identify implant overpayments, uncover reimbursement opportunities, and make more informed purchasing decisions.

As hospitals continue to focus on margin improvement and supply-chain optimization, the Company is uniquely positioned at the intersection of healthcare cost containment, medical devices, and data-driven decision support.

Business Highlights

• Structural cost advantage. Factory-direct pricing on devices otherwise sold by major brand-name distributors, highly compelling to cost-pressured hospitals and surgery centers.

• Regulatory-ready portfolio. FDA-cleared, ISO 13485 product lines.

• Established 30+ year supply relationship. Proven, stable manufacturing partner with deep product breadth and OEM capability.

• Diversified revenue. Multiple product categories plus OEM / private-label income from other device companies.

• Scalable channels. National distribution complemented by a low-friction healthcare e-commerce channel.

• Built-in technology upside. Proprietary hospital cost-intelligence software included — optionality for a strategic acquirer with no extra cost basis.

• Transition support. Ownership open to a structured handover to ensure continuity of supply and relationships.

Transaction & Target Counterparty

Why Now?

Hospitals and ambulatory surgery centers are under sustained pressure to reduce implant and device costs without sacrificing quality. This platform delivers FDA-cleared, premium-equivalent devices at a fraction of brand-name pricing, positioning an acquirer to capture share in a large, cost-sensitive market while adding an established supply chain and a built-in analytics capability.

Next Steps

Qualified, verified parties may receive the Confidential Information Memorandum upon execution of a non-disclosure agreement. To request the NDA or schedule an introductory call, contact the advisory team below.

Todd Dyste — Business Advisor, Transworld Business Advisors NorthStar
tdyste@tworld.com · Cell (612)325-5399  ·  Office (888) 290-5232
3800 American Blvd. Suite 760, Bloomington, MN 55431 · www.TworldNorthStar.com
In partnership with M&A Group — Member FINRA / SIPC (securities & capital markets advisory)

Transaction Summary

Deal Type:                       Asset (open to other structures)

Real Estate:                    N/A

Founder Transition:       Available

Pricing:                            $70,000,000 USD

Process:                          NDA-gated; full CIM available to qualified parties

Additional Instructions:

If you are interested in learning more, please provide your contact information in the white box on the right side of the screen so that an NDA can be emailed to you. Once you receive and sign the NDA via DocuSign, please watch your inbox for an email from Carter Olson (colson@tworld.com) containing a secure link and password to access additional information about the business.  

Note: If you don’t see the emails right away, be sure to check your junk or spam folder, sometimes they land there by mistake.